secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2022-04-14T23:59:59+00:00
Accession:  0001193125-22-105729
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology CSO Ronald Herbst resigns; Jan Pinkas promoted to CSO
--------------------------------------------------------------------

- Ronald Herbst, Ph.D. resigned as CSO effective April 12, 2022; Mark Chin resigned from Board same day.
- Jan Pinkas, Ph.D., formerly SVP Preclinical R&D, promoted to CSO effective April 12, 2022.
- Company reaffirms IND filings for PYX-201 (Anti-EDB) and PYX-106 (Anti-Siglec-15) expected in 2H22.
- Neither departure was due to any disagreement with the company or Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312522105729/0001193125-22-105729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312522105729/d331497d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-105729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer